drugset / Trial / NCT02361346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.
Timeline
- Start
- 2015-02
- Primary completion
- 2021-03-22
- Completion
- 2021-03-22
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision following clinical hold”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-3724 | Unknown | 5 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 10 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 20 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 50 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 75 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 100 ug/kg | Intravenous |